1,3-indandione has been researched along with Alzheimer Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Admane, P; Annapragada, AV; Eriksen, JL; Starosolski, ZA; Sun, X; Tanifum, EA | 1 |
| Kumari, S; Manral, A; Mishra, CB; Saini, V; Tiwari, M | 1 |
2 other study(ies) available for 1,3-indandione and Alzheimer Disease
| Article | Year |
|---|---|
1-Indanone and 1,3-indandione Derivatives as Ligands for Misfolded α-Synuclein Aggregates.
Topics: alpha-Synuclein; Alzheimer Disease; Dose-Response Relationship, Drug; Drug Design; Humans; Indans; Ligands; Molecular Structure; Neuroprotective Agents; Protein Aggregates; Protein Folding; Structure-Activity Relationship | 2022 |
Design, synthesis and evaluation of novel indandione derivatives as multifunctional agents with cholinesterase inhibition, anti-β-amyloid aggregation, antioxidant and neuroprotection properties against Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Cell Line; Cholinesterase Inhibitors; Drug Design; Drug Evaluation, Preclinical; Humans; Hydrogen Peroxide; Indans; Kinetics; Microscopy, Electron, Transmission; Neuroprotective Agents | 2016 |